[go: up one dir, main page]

DK0671942T3 - Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf - Google Patents

Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf

Info

Publication number
DK0671942T3
DK0671942T3 DK93902271T DK93902271T DK0671942T3 DK 0671942 T3 DK0671942 T3 DK 0671942T3 DK 93902271 T DK93902271 T DK 93902271T DK 93902271 T DK93902271 T DK 93902271T DK 0671942 T3 DK0671942 T3 DK 0671942T3
Authority
DK
Denmark
Prior art keywords
beta
pct
antibiotic
pharmaceutical composition
lactam antibiotic
Prior art date
Application number
DK93902271T
Other languages
Danish (da)
English (en)
Inventor
Pekka Heino
Original Assignee
Remedy Consulting Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Consulting Oy filed Critical Remedy Consulting Oy
Application granted granted Critical
Publication of DK0671942T3 publication Critical patent/DK0671942T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/56Protease inhibitors from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004Amidase (3.5.1.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cephalosporin Compounds (AREA)
DK93902271T 1992-01-17 1993-01-18 Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf DK0671942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.
PCT/FI1993/000016 WO1993013795A1 (en) 1992-01-17 1993-01-18 Medical use, a medical method and a pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DK0671942T3 true DK0671942T3 (da) 1999-08-23

Family

ID=8534042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93902271T DK0671942T3 (da) 1992-01-17 1993-01-18 Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf

Country Status (9)

Country Link
US (1) US5607671A (fi)
EP (1) EP0671942B1 (fi)
AT (1) ATE174513T1 (fi)
DE (1) DE69322659T2 (fi)
DK (1) DK0671942T3 (fi)
ES (1) ES2129078T3 (fi)
FI (1) FI920206A0 (fi)
GR (1) GR3029699T3 (fi)
WO (1) WO1993013795A1 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0913151T3 (da) * 1996-05-09 2002-10-14 Sankyo Co Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
FI20020332A0 (fi) * 2002-02-20 2002-02-20 Heino Pekka Untamo Valmiste ja menetelmä painon pudottamiseksi
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
EP2162119A2 (en) * 2007-05-21 2010-03-17 Phenomix Corporation Stable pharmaceutical formulation for a dpp-iv inhibitor
ITBO20080297A1 (it) * 2008-05-16 2009-11-17 Archimede R & D S R L Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
ITMI20121715A1 (it) * 2012-10-11 2014-04-12 Bioikos Ambiente S R L Composizioni farmaceutiche con ridotto impatto ambientale
JP6685925B2 (ja) 2014-04-17 2020-04-22 シンセティック バイオロジクス,インコーポレイテッド 治療用として改善された特性を有するβ−ラクタマーゼ
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス,インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
ES2806426T3 (es) * 2014-10-08 2021-02-17 Synthetic Biologics Inc Formulaciones de betalactamasas y usos de las mismas
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
WO2016137993A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
WO2016144856A1 (en) 2015-03-06 2016-09-15 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2017144495A1 (en) 2016-02-23 2017-08-31 Da Volterra Beta-lactamase variants
ES2922009T3 (es) 2016-02-23 2022-09-06 Da Volterra Variantes de beta-lactamasa
CN111247246A (zh) 2017-10-25 2020-06-05 达·沃尔泰拉公司 β-内酰胺酶变体
KR20220006072A (ko) * 2019-05-06 2022-01-14 신세틱 바이오로직스, 인코퍼레이티드 이식편대숙주병의 치료를 위한 베타-락타마제 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613624B1 (fr) * 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle

Also Published As

Publication number Publication date
US5607671A (en) 1997-03-04
FI920206A0 (fi) 1992-01-17
WO1993013795A1 (en) 1993-07-22
DE69322659D1 (de) 1999-01-28
ES2129078T3 (es) 1999-06-01
EP0671942B1 (en) 1998-12-16
ATE174513T1 (de) 1999-01-15
EP0671942A1 (en) 1995-09-20
DE69322659T2 (de) 2000-01-05
GR3029699T3 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
DK0671942T3 (da) Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf
MY124714A (en) Enzyme treatment
NO20014507L (no) Legemiddel for behandling av sukkersyke
NZ510690A (en) Methods for administration of antibiotics
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
EP1024827A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF ORAL VACCINES AND THERAPEUTICS
FR2700117B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
ME00578A (en) Use of gastrointestinal lipase inhibitors
ATE337712T1 (de) Zusammensetzung zur intestinalen verabreichung
NO923643D0 (no) Legemiddel for behandling av gastrointestinale forstyrrelser
DE69622855D1 (de) Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten
ATE246192T1 (de) Ethyliden-derivate tricyclyscher carbapenems
DE69933925D1 (de) Verbesserte methode zur eradikation von helicobacter pylori
DE69418218D1 (de) Chinolonylcarboxamidocephalosporin-derivate und diese enthaltende arzneimittel
Rosenberg et al. Antibiotic TA: an adherent antibiotic
DE602004017586D1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
ATE212229T1 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
RU93000551A (ru) Лекарственное средство мазь лингезин
UA31364A (uk) Спосіб лікування дисбактеріозу кишечнику у хворих на гострий пієлонефрит
BRPI0403271A (pt) composição de liberação in vivo